Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA takeover offer by Bain Capital and Cinven successful

  • 18/08/2017
  • Press Release
  • Investor News
  • 63.85 percent of the STADA shares outstanding were tendered within the scope of the renewed voluntary public takeover offer from Bain Capital and Cinven; minimum acceptance threshold of 63 percent thus exceeded
  • Further acceptance period until September 1, 2017 for shareholders who have not yet accepted the offer


Bad Vilbel, August 18, 2017 –

Nidda Healthcare Holding AG, the acquiring company of Bain Capital und Cinven, announced today that 63.85 percent of the outstanding STADA shares were tendered within the scope of the renewed voluntary public takeover offer. The minimum acceptance threshold of 63 percent was thus exceeded. The acceptance period ended on August 16, 2017 at midnight (24:00 CEST).


As stipulated in the German Securities Acquisition and Transfer Act (WpÜG), after the achievement of the minimum acceptance rate, a further acceptance period of two weeks follows. This commences on August 19, 2017 and expires on September 1, 2017. During this period, STADA shareholders who have not yet accepted the offer have the opportunity to tender their shares.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. STADA is represented in more than 30 countries with approximately 50 sales companies worldwide. Branded products such as Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2016, STADA achieved adjusted Group sales of Euro 2,167.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 398 million and adjusted net income of Euro 177.3 million. As of December 31, 2016, STADA employed approximately 10,900 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]